BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zocaglusagene nuzaparvovec readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zocaglusagene nuzaparvovec\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04174105-11065@assetmemo.bio
DTSTAMP:20261121T010012Z
DTSTART;VALUE=DATE:20350228
DTEND;VALUE=DATE:20350301
SUMMARY:Zocaglusagene nuzaparvovec: Phase 1/2 readout est. (NCT04174105)
DESCRIPTION:Zocaglusagene nuzaparvovec\, phase 1/2\, Pompe Disease.\nStudy:
  Gene Transfer Study in Patients With Late Onset Pompe Disease\nEstimated 
 primary completion: 28 February 2035. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zocaglusagene-nuzaparvovec#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04174105
URL:https://assetmemo.bio/drug/zocaglusagene-nuzaparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
